MedDataX Logo

Livalo Acute Myocardial Infarction Study (LAMIS)

NCT ID: NCT01265706

Last Updated: 2014-12-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-07-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is performed to observe the incidence of major cardiovascular events in Korean patients with AMI after giving pitavastatin 2mg and 4mg longer than 1 year.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myocardial Infarction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with STEMI, NSTEMI
* Patients satisfying at least one of the followings

1. Patients with LDL-C ≥ 130 mg/dL
2. Patients with LDL-C ≥ 100 mg/dL who are regarded as required cholesterol lowering therapy by the investigator
3. Patients taking statin are required continuous cholesterol lowering therapy
* Patients satisfying at least two of the followings

1. The change of Ischemic ECG
2. CK, CK-MB, Troponin-I increased more than two times
3. The symptom of ACS

Exclusion Criteria

1. Patients with in-stent restenosis after PCI or coronary artery bypass
2. Patients with cardiogenic shock
3. Patients with severe heart failure (Left ventricular ejection fraction is less than 30%)
4. Patients who are taking cyclosporine
5. Patients who experienced hypersensitivity to pitavastatin
6. Patients under dialysis treatment
7. Patients who are participating other clinical trials
8. Patients who can not stop taking concomitant drugs
9. Pregnant or lactating women or suspected pregnancy
10. Patients who are regarded as ineligible for this study by the investigator
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

JW Pharmaceutical

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Young Jun Hong

Role: PRINCIPAL_INVESTIGATOR

Chonnam National University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chonnam National University Hospital

Gwangju, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PTV_LAMIS II

Identifier Type: -

Identifier Source: org_study_id